Clinical trial WO29636
WO29636 A Phase III, Open-Label, Multicenter, Randomized Study Of Atezolizumab (Anti?Pd-L1 Antibody) Versus Observation As Adjuvant Therapy In Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection
Cancers | |
---|---|
Organ | Ureters - bladder - urethra |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Roche |
EudraCT Identifier | 2014-005603-25 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02450331 |
Inclusion criteria | Absence of metastasis |
Last update |